NeoGenomics, Inc. (NEO)
Market Cap | 1.97B |
Revenue (ttm) | 610.66M |
Net Income (ttm) | -84.23M |
Shares Out | 127.71M |
EPS (ttm) | -0.66 |
PE Ratio | n/a |
Forward PE | 495.53 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 545,907 |
Open | 15.98 |
Previous Close | 15.63 |
Day's Range | 15.31 - 16.12 |
52-Week Range | 11.03 - 21.22 |
Beta | 1.12 |
Analysts | Strong Buy |
Price Target | 19.78 (+28.44%) |
Earnings Date | Apr 30, 2024 |
About NEO
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detect... [Read more]
Financial Performance
In 2023, NeoGenomics's revenue was $591.64 million, an increase of 16.07% compared to the previous year's $509.73 million. Losses were -$87.97 million, -39.02% less than in 2022.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for NEO stock is "Strong Buy." The 12-month stock price forecast is $19.78, which is an increase of 28.44% from the latest price.
News
NeoGenomics Reports First Quarter 2024 Results
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. announced its first-quarter results for the period ended March 31, 2024.
NeoGenomics Announces Senior Leadership Promotions
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc., announced two promotions within its senior leadership team, effective immediately.
NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its first quarter 2024 financial results on Tuesday, April 30, 2024.
NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present data at AACR, showing its commitment to advancing cancer patient care through innovative research & development initiatives.
NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics released its 2023 ESG Report, measuring key sustainability focus areas – quality, integrity, accountability, teamwork, and innovation.
NeoGenomics to Participate in the TD Cowen 44th Annual Health Care Conference
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. will participate in the upcoming TD Cowen 44th Annual Health Care Conference in Boston, Mass.
NeoGenomics stock surged but technicals point to a pullback
NeoGenomics (NASDAQ: NEO) stock price popped sharply this week after the company published strong financial results. It soared to a high of $16.50, its highest point since December 29th.
NeoGenomics Reports Fourth Quarter and Full Year 2023 Results
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. today announced fourth quarter and full year 2023 results for the period ended December 31, 2023.
NeoGenomics Signs Working with Cancer Pledge in Support of Employees
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics has signed the Working with Cancer Pledge to support team members living with or caring for a loved one with cancer.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeoGenomics, Inc. - NEO
NEW YORK , Jan. 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ: NEO). Such investors are advised to...
NeoGenomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20, 2024
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc., will report its fourth quarter and full year 2023 financial results on Tuesday, February 20, 2024.
ROSEN, A LEADING NATIONAL FIRM, Encourages NeoGenomics, Inc. Investors to Inquire About Securities Class Action Investigation – NEO
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of NeoGenomics, Inc. (NASDAQ: NEO...
NeoGenomics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco and will present on Monday, Jan. 8, 8:15 p.m. ET.
NeoGenomics to Appeal Ruling
FORT MYERS, FL / ACCESSWIRE / December 28, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced that NeoGenomics Laboratories, Inc., a su...
NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response
FT. MYERS, FL / ACCESSWIRE / December 5, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced new data highlighting its RaDaR® assay for minimal residual...
NeoGenomics to Participate at the Piper Sandler 35th Annual Healthcare Conference
FT. MYERS, FL / ACCESSWIRE / November 14, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced the company will participate in the upcoming Piper Sandler...
NeoGenomics Reports Third Quarter 2023 Results
Third Quarter Revenue Increased 18% to $152 Million FORT MYERS, FL / ACCESSWIRE / November 6, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today ...
NeoGenomics Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios
Neo Comprehensive™ - Heme Cancers is a large and comprehensive next-generation sequencing panel with broad coverage of genes associated with blood cancers Early-stage NSCLC Panel - a therapy selection...
NeoGenomics to Report Third Quarter 2023 Financial Results on November 6, 2023
FT. MYERS, FL / ACCESSWIRE / October 17, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced that it will report its th...
NeoGenomics Reports Second Quarter 2023 Results
Second Quarter Revenue Increased 18% to $147 Million FORT MYERS, FL / ACCESSWIRE / August 8, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today a...
NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer
FT. MYERS, FL / ACCESSWIRE / July 27, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, announced today that the Molecular Diagnostics Services Program (MolDx) has co...
NeoGenomics to Report Second Quarter 2023 Financial Results on August 8, 2023
FT. MYERS, FL / ACCESSWIRE / July 18, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced that it will report its secon...
Press release Biocartis Group NV: Biocartis appoints George Cardoza as new CFO and Head of Service Delivery
PRESS RELEASE - INSIDE INFORMATION/ REGULATED INFORMATION 18 July 202 3 , 7:00 AM CE S T
NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors
FT. MYERS, FL / ACCESSWIRE / June 29, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced the appointment of Elizabeth ...
NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage
FT. MYERS, FL / ACCESSWIRE / June 15, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced that its RaDaR® assay, a pers...